JP2013543881A5 - - Google Patents

Download PDF

Info

Publication number
JP2013543881A5
JP2013543881A5 JP2013540410A JP2013540410A JP2013543881A5 JP 2013543881 A5 JP2013543881 A5 JP 2013543881A5 JP 2013540410 A JP2013540410 A JP 2013540410A JP 2013540410 A JP2013540410 A JP 2013540410A JP 2013543881 A5 JP2013543881 A5 JP 2013543881A5
Authority
JP
Japan
Prior art keywords
formulation
mesoporous silica
active ingredient
range
croscarmellose sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013540410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013543881A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/071186 external-priority patent/WO2012072580A1/en
Publication of JP2013543881A publication Critical patent/JP2013543881A/ja
Publication of JP2013543881A5 publication Critical patent/JP2013543881A5/ja
Pending legal-status Critical Current

Links

JP2013540410A 2010-11-29 2011-11-28 秩序化したメソポーラスシリカの圧縮製剤 Pending JP2013543881A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10192938 2010-11-29
EP10192938.8 2010-11-29
PCT/EP2011/071186 WO2012072580A1 (en) 2010-11-29 2011-11-28 Compressed formulations of ordered mesoporous silicas

Publications (2)

Publication Number Publication Date
JP2013543881A JP2013543881A (ja) 2013-12-09
JP2013543881A5 true JP2013543881A5 (enExample) 2014-03-06

Family

ID=43827090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013540410A Pending JP2013543881A (ja) 2010-11-29 2011-11-28 秩序化したメソポーラスシリカの圧縮製剤

Country Status (6)

Country Link
US (1) US20130243833A1 (enExample)
EP (1) EP2646005B1 (enExample)
JP (1) JP2013543881A (enExample)
ES (1) ES2744926T3 (enExample)
PL (1) PL2646005T3 (enExample)
WO (1) WO2012072580A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201212866D0 (en) * 2012-07-20 2012-09-05 Formac Pharmaceuticals Nv Dry granulates of mesoporous silica powders
US20170246111A1 (en) 2014-09-15 2017-08-31 Pharmasol Gmbh Active-loaded particulate materials for topical administration
KR20210089210A (ko) 2018-11-07 2021-07-15 디스럽티브 매터리얼즈 파마 아베 실질적 비정질인 메조포러스 탄산마그네슘을 포함하는 신규한 비정질 활성 제약 성분

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE275600T1 (de) * 1997-12-09 2004-09-15 Sba Materials Inc Blockcopolymerverarbeitung für mesostrukturierte anorganische oxidmaterialien
US20060018966A1 (en) 2003-07-22 2006-01-26 Lin Victor S Antimicrobial mesoporous silica nanoparticles
US7563451B2 (en) * 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
AU2009242175B2 (en) * 2008-04-28 2013-02-07 Formac Pharmaceuticals N.V. Ordered mesoporous silica material
EA021313B1 (ru) * 2009-02-06 2015-05-29 Джилид Сайэнс, Инк. Таблетки для комбинированной терапии

Similar Documents

Publication Publication Date Title
JP2015007131A5 (enExample)
NZ729172A (en) Combination formulation of two antiviral compounds
JP2015078230A5 (enExample)
JP2010527347A5 (enExample)
JP2010132654A5 (enExample)
JP2015511635A5 (enExample)
HRP20171512T1 (hr) Derivati betulina
JP2014205701A5 (enExample)
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
JP2010534220A5 (enExample)
MX2011007817A (es) Formulacion farmaceutica o alimenticia de liberacion controlada y proceso para su preparacion.
SI3124018T1 (en) Oral formulations of deferasirox
HRP20171824T1 (hr) (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A
JP2015533129A (ja) チカグレロルを含む固形経口医薬製剤
JP2015514739A5 (enExample)
JP2013166781A5 (enExample)
JP2013543881A5 (enExample)
JP2009542678A5 (enExample)
RU2015143475A (ru) Продукт и способ лечения диареи
MX374106B (es) Una composicion farmaceutica que contiene candesartan cilexetilo y amlodipina.
JP2015129124A5 (enExample)
IT1401284B1 (it) Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
JP2015129175A5 (enExample)
JP2017520619A5 (enExample)